# Esophageal Cancer Research and Treatment

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/esophageal-cancer-research-and-treatment/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, treatment, and management of esophageal cancer, with an emphasis on preoperative chemoradiotherapy, surgery, chemoradiation, and endoscopic resection. It also covers topics such as Barrett's esophagus, neoadjuvant therapy, adenocarcinoma, meta-analyses, and epidemiological trends. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10619 |
| Works | 593 |

## Topic papers all

Showing 15 of 593.

- [Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer](https://scholariq.org/papers/human-papillomavirus-and-survival-of-patients-with-oropharyngeal-cancer/)
- [Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer](https://scholariq.org/papers/preoperative-chemoradiotherapy-for-esophageal-or-junctional-cancer/)
- [The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project-proposals-for-revision-of-the-tnm-stage/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer](https://scholariq.org/papers/concurrent-chemotherapy-and-radiotherapy-for-organ-preservation-in-advanced/)
- [Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial](https://scholariq.org/papers/neoadjuvant-chemoradiotherapy-plus-surgery-versus-surgery-alone-for-oesophageal/)
- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro/)
- [STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery](https://scholariq.org/papers/strocss-2021-strengthening-the-reporting-of-cohort-cross-sectional-and-case/)
- [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial](https://scholariq.org/papers/preoperative-radiotherapy-combined-with-total-mesorectal-excision-for-resectable/)
- [Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/meta-analysis-of-concomitant-versus-sequential-radiochemotherapy-in-locally/)
- [Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer](https://scholariq.org/papers/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/)
- [Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial](https://scholariq.org/papers/surgical-treatment-of-gastric-cancer-15-year-follow-up-results-of-the-randomised/)
- [Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial](https://scholariq.org/papers/minimally-invasive-versus-open-oesophagectomy-for-patients-with-oesophageal/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)

## Topic primary papers

Showing 15 of 208.

- [Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer](https://scholariq.org/papers/preoperative-chemoradiotherapy-for-esophageal-or-junctional-cancer/)
- [Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial](https://scholariq.org/papers/neoadjuvant-chemoradiotherapy-plus-surgery-versus-surgery-alone-for-oesophageal/)
- [Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer](https://scholariq.org/papers/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/)
- [Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial](https://scholariq.org/papers/minimally-invasive-versus-open-oesophagectomy-for-patients-with-oesophageal/)
- [Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018](https://scholariq.org/papers/burden-and-cost-of-gastrointestinal-liver-and-pancreatic-diseases-in-the-united/)
- [Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus](https://scholariq.org/papers/extended-transthoracic-resection-compared-with-limited-transhiatal-resection-for-2/)
- [Radiofrequency Ablation in Barrett's Esophagus with Dysplasia](https://scholariq.org/papers/radiofrequency-ablation-in-barrett-s-esophagus-with-dysplasia/)
- [Incidence of Adenocarcinoma among Patients with Barrett's Esophagus](https://scholariq.org/papers/incidence-of-adenocarcinoma-among-patients-with-barrett-s-esophagus/)
- [Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781](https://scholariq.org/papers/phase-iii-trial-of-trimodality-therapy-with-cisplatin-fluorouracil-radiotherapy/)
- [Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer](https://scholariq.org/papers/chemotherapy-followed-by-surgery-compared-with-surgery-alone-for-localized/)
- [INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy](https://scholariq.org/papers/int-0123-radiation-therapy-oncology-group-94-05-phase-iii-trial-of-combined/)
- [Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline](https://scholariq.org/papers/endoscopic-submucosal-dissection-european-society-of-gastrointestinal-endoscopy/)
- [Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus](https://scholariq.org/papers/chemoradiation-with-and-without-surgery-in-patients-with-locally-advanced/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy](https://scholariq.org/papers/int-0123-radiation-therapy-oncology-group-94-05-phase-iii-trial-of-combined-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.